12.10.19
Sanofi has entered an agreement to acquire Synthorx, a CA-based immuno-oncology company, for $2.5 billion, enhancing its cancer and autoimmune pipeline.
Sanofi gains Synthorx’s lead investigational immuno-oncology candidate, THOR-707, in phase 1/2 development as a single agent and in combination with another type of immunotherapy drug to address multiple tumor types. THOR-707, a variant of immune system molecule interleukin-2, leverages the immune system to destroy tumors by increasing the immune system cells that destroy damaged cells. Research to date shows the compound requires fewer doses than other interleukin-2 products, potentially reducing dangerous side effects.
The company has two other immuno-oncology candidates in the pipeline and one candidate for autoimmune disorders. Sanofi and Synthorx also aim to explore combination opportunities with Sanofi's clinical and preclinical programs.
Paul Hudson, Sanofi’s chief executive officer said, “This acquisition fits perfectly with our strategy to build a portfolio of high-quality assets and to lead with innovation. Additionally, it is aligned with our goal to build our oncology franchise with potentially practice-changing medicines and novel combinations.”
Sanofi gains Synthorx’s lead investigational immuno-oncology candidate, THOR-707, in phase 1/2 development as a single agent and in combination with another type of immunotherapy drug to address multiple tumor types. THOR-707, a variant of immune system molecule interleukin-2, leverages the immune system to destroy tumors by increasing the immune system cells that destroy damaged cells. Research to date shows the compound requires fewer doses than other interleukin-2 products, potentially reducing dangerous side effects.
The company has two other immuno-oncology candidates in the pipeline and one candidate for autoimmune disorders. Sanofi and Synthorx also aim to explore combination opportunities with Sanofi's clinical and preclinical programs.
Paul Hudson, Sanofi’s chief executive officer said, “This acquisition fits perfectly with our strategy to build a portfolio of high-quality assets and to lead with innovation. Additionally, it is aligned with our goal to build our oncology franchise with potentially practice-changing medicines and novel combinations.”
